Morning Industry Symposium:
Time to start CDK4&6 inhibition in EBC: Verzenio in HR+ HER2- node positive EBC at high risk of recurrence
Supported by Lilly
Saturday, October 15, 2022 Hall B (Great Hall 2)
Breakfast will be served from 07:00-07:30, half an hour prior to the start of the session.
Admission to this symposium is included as part of the congress registration.
|Chairperson:||Richard de Boer, Melbourne, Australia|
|07:30-07:50||Verzenio’s efficacy in node positive early breast cancer at high risk of recurrence
Alistair Ring, London, UK
|07:50-08:10||Verzenio safety and tolerability: Learnings from MonarchE and food tolerability study
Fran Boyle, Sydney, Australia
||A Verzenio EBC case study to open panel discussion
Catherine Shannon, Brisbane, Australia
||Panel discussion + Q&A from audience|